Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2007

View Archived Issues

Trial results support further investigation of sunitinib in non-small cell lung cancer

Clinical benefit seen with nimotuzumab in non-small cell lung cancer

Degarelix suppresses PSA, testosterone in prostate cancer patients

Sleep maintenance promoting effects of the 5-HT2A receptor antagonist eplivanserin shown in rats

Single-agent talactoferrin improves survival in refractory non-small cell lung cancer

Preclinical characterization of ARH-460-16-2, a novel anti-CD44 MAb

Telmisartan exerts potent PPAR-gamma-mediated antiproliferative activity against PC cells

Inhibition of calcineurin activity using tacrolimus restores memory in a mouse model of AD

Zelos reports positive results of phase I and II trials of Ostabolin-C

Studies reveal increased bone formation with anti-sclerostin antibody

Topical amitriptyline ineffective in treating neuropathic pain

Chelsea reports plans for phase III trials of droxidopa for NOH

Ariad begins phase III trial of deforolimus for metastatic soft-tissue and bone sarcomas

Positive results for DOV Pharmaceutical's phase Ib trial of DOV-21947

Encysive will conduct additional phase III study of Thelin in PAH

Cell Therapeutics begins FDA-approved, phase III advanced NSCLC trial in women

Inflazyme and Biolipox to enter asset purchase agreement

Lundbeck in-licenses Circadin from Neurim

Phase I clinical trial approved for transdermal oxycodone

EMEA grants orphan drug designation to HDAC inhibitor MGCD-0103

Allos completes interim analyses of pivotal phase II trial of PDX for PTCL

Array BioPharma and Celgene sign cancer and inflammation therapeutics agreement

Update on Progen's development of PI-88 for cancer

Schering-Plough begins phase I trial of PS-948115 for respiratory disease

AstraZeneca acquires North American rights to Verus' asthma development programs

In vivo Gram-positive antibacterial activity of novel oxazolidinone compounds

Biodel's two ongoing pivotal phase III trials of VIAject to include European sites

Recent patents divulge novel analgesic agents

Recent patents disclose new anxiolytic, antidepressive and antipsychotic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...